Poole Christopher V, Carlton Donna, Bimbo Lisa, Allon Michael
Division of Nephrology, University of Alabama at Birmingham, 35233, USA.
Nephrol Dial Transplant. 2004 May;19(5):1237-44. doi: 10.1093/ndt/gfh041. Epub 2004 Feb 19.
The standard therapy of dialysis catheter-related bacteraemia involves both systemic antibiotics and catheter replacement. We reported recently that instillation of an antibiotic lock (highly concentrated antibiotic solution) into the catheter lumen after dialysis sessions, in conjunction with systemic antibiotics, can successfully treat many episodes of catheter-related bacteraemia without requiring catheter removal. The present study evaluated whether the likelihood of achieving a cure with this protocol depends on the type of pathogen.
This was a historically controlled interventional study of an antibiotic lock protocol for the treatment of catheter-related bacteraemia. We analysed prospectively the likelihood of clinical cure (fever resolution and negative surveillance cultures) with an antibiotic lock protocol among patients with dialysis catheter-related bacteraemia. In addition, infection-free catheter survival was evaluated for up to 150 days, and compared with that observed among patients managed with routine catheter replacement.
Overall, the antibiotic lock protocol was successful in 33 of 47 infected patients (70%) with catheter-related bacteraemia. The likelihood of a clinical cure was 87% for Gram-negative infections, 75% for Staphylococcus epidermidis infections, and only 40% for Staphylococcus aureus infections (P = 0.04). The median infection-free catheter survival with the antibiotic lock protocol was longer than that observed among patients with routine catheter replacement (154 vs 71 days, P = 0.02).
The clinical success of an antibiotic lock protocol in eradicating catheter-related bacteraemia while salvaging the catheter is highly dependent on the bacterial pathogen. Thus, the overall success rate in an individual dialysis programme will depend on the relative frequencies of different bacterial pathogens.
透析导管相关菌血症的标准治疗包括全身使用抗生素和更换导管。我们最近报道,透析后将抗生素封管液(高浓度抗生素溶液)注入导管腔,联合全身使用抗生素,可成功治疗许多导管相关菌血症病例,而无需拔除导管。本研究评估了采用该方案治愈的可能性是否取决于病原体类型。
这是一项针对治疗导管相关菌血症的抗生素封管方案的历史性对照干预研究。我们前瞻性分析了采用抗生素封管方案治疗透析导管相关菌血症患者临床治愈(发热消退且监测培养阴性)的可能性。此外,评估了无感染导管存活长达150天的情况,并与采用常规导管更换治疗的患者进行比较。
总体而言,抗生素封管方案在47例导管相关菌血症感染患者中有33例(70%)取得成功。革兰阴性菌感染的临床治愈率为87%,表皮葡萄球菌感染为75%,而金黄色葡萄球菌感染仅为40%(P = 0.04)。采用抗生素封管方案的无感染导管存活时间中位数长于采用常规导管更换治疗的患者(154天对71天,P = 0.02)。
抗生素封管方案在根除导管相关菌血症并保留导管方面的临床成功高度依赖于细菌病原体。因此,个体透析项目的总体成功率将取决于不同细菌病原体的相对频率。